Hologic (NASDAQ:HOLX) Reaches New 1-Year Low - Here's What Happened

Hologic, Inc. (NASDAQ:HOLX - Get Free Report)'s stock price reached a new 52-week low on Monday . The stock traded as low as $55.89 and last traded at $57.17, with a volume of 6818925 shares changing hands. The stock had previously closed at $56.50.

Analysts Set New Price Targets

HOLX has been the topic of several research analyst reports. Evercore ISI decreased their price objective on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a research report on Thursday, February 6th. Morgan Stanley lowered their price objective on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Leerink Partnrs lowered shares of Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Raymond James reissued an "outperform" rating and issued a $90.00 target price (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Finally, Citigroup dropped their price target on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $84.62.

Hologic Stock Down 0.5 %

The company's 50-day simple moving average is $61.02 and its two-hundred day simple moving average is $70.06. The firm has a market cap of $13.02 billion, a PE ratio of 18.30, a PEG ratio of 2.14 and a beta of 0.82. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HOLX. General Partner Inc. purchased a new stake in shares of Hologic during the fourth quarter valued at approximately $26,000. Venturi Wealth Management LLC lifted its position in Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after acquiring an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 260 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares in the last quarter. Finally, Smithfield Trust Co raised its stake in shares of Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 400 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.